Management of Hypertension
Once purchased the link emailed to you is valid for 60 days. If you do not complete the course within 60 days call the FPA office and we will resend the link to complete the course.
FPA Correspondence Course
Approved for Florida Consultant Recertification
3 Contact Hours or 0.3 CEUs
Educational Needs Assessment
often referred to as high blood pressure, is the most common condition seen in primary care and leads to
myocardial infarction, stroke, renal failure, and death if not detected early
and treated appropriately. Hypertension affects 1 billion people worldwide and is the number one reason listed for office visits. The Eighth Joint National Committee (JNC8) focused on a rigorous, evidence-based
approach to recommend treatment thresholds, goals, and medications in the management of hypertension in adults. The home study will provide a detailed review of hypertension and evidence based recommendations
for the management of high blood pressure.
At the completion of this activity, pharmacists will be able to: Explain the prevalence and etiology associated with hypertension; Know the epidemiology of hypertension in the United States; Identify the pathophysiology of primary and secondary hypertension; Describe the clinical presentation and the complications that result from hypertension; Provide examples of lifestyle modifications that are vital to the prevention and management of hypertension; Summarize changes in new JNC guidelines; Compare and contrast the various pharmacological agents used to treat hypertension; Select appropriate antihypertensive therapy for patients with comorbid diseases and pregnancy; Identify the role of the pharmacist in the management of hypertension.
Association is accredited by the Accreditation Council for Pharmacy Education
as a provider of continuing pharmacy education.
Three (3) contact hours are available upon completion of the posttest questions and evaluation form. You must pass the exam with a score of 70% or better.
This is an ACPE knowledge-based activity. Initial Release Date: October 1, 2017. Expiration
October 1, 2020.
Florida Board of
Pharmacy approval number 20-594633.